Amifampridine is a potassium channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and pediatric patients 6 years of age and older. It is available as tablets for oral use. MedsAcross supplies Amifampridine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
FIRDAPSE ® is indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and pediatric patients 6 years of age and older. FIRDAPSE is a potassium channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and pediatric patients 6 years of age and older.
Source: US FDA prescribing information
The mechanism by which amifampridine exerts its therapeutic effect in LEMS patients has not been fully elucidated. Amifampridine is a broad-spectrum potassium channel blocker.
Source: US FDA prescribing information
Administer orally in divided doses (3 to 5 times daily). The recommended starting dosage for adults (any weight) and pediatric patients weighing 45 kg or more is 15 mg to 30 mg daily, in divided doses. Dosage can be increased by 5 mg daily every 3 to 4 days. The maximum single dose is 20 mg. Dosage is not to exceed a maximum of 100 mg daily. The recommended starting dosage for pediatric patients weighing less than 45 kg is 5 mg to 15 mg daily, in divided doses. Dosage can be increased by 2.5 mg daily every 3 to 4 days. The maximum single dose is 10 mg. Dosage is not to exceed a maximum of 50 mg daily. The recommended starting dosage for adult and pediatric patients with renal impairment, hepatic impairment, and in known N-acetyltransferase 2 (NAT2) poor metabolizers is the lowest recommended initial daily dosage.
Source: US FDA prescribing information
FIRDAPSE is contraindicated in patients with: A history of seizures Hypersensitivity to amifampridine phosphate or another aminopyridine FIRDAPSE is contraindicated in patients with: A history of seizures. Hypersensitivity to amifampridine or another aminopyridine
Source: US FDA prescribing information
Seizures: FIRDAPSE can cause seizures. Consider discontinuation or dose-reduction of FIRDAPSE in patients who have a seizure while on treatment. Hypersensitivity reactions: If a hypersensitivity reaction such as anaphylaxis occurs, FIRDAPSE should be discontinued and appropriate therapy initiated.
Source: US FDA prescribing information
The following serious adverse reactions are described elsewhere in the labeling: Seizures Hypersensitivity The most common (> 10%) adverse reactions are: paresthesia, upper respiratory tract infection, abdominal pain, nausea, diarrhea, headache, elevated liver enzymes, back pain, hypertension, and muscle spasms.
Source: US FDA prescribing information
Drugs that lower seizure threshold: Concomitant use may lead to an increased risk of seizures. Drugs with cholinergic effects (e.g., direct or indirect cholinesterase inhibitors): Concomitant use may increase the cholinergic effects of FIRDAPSE and of those drugs and increase the risk of adverse reactions.
Source: US FDA prescribing information
Store FIRDAPSE tablets at 20°C to 25°C (68°F to 77°F) with excursions permitted from 15°C to 30°C (59°F to 86°F). See Dosage and Administration for storage instructions for FIRDAPSE prepared suspension.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Amifampridine, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Firdapse 10 mg tabletOral | Catalyst Pharmaceuticals | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 1 presentations of Amifampridine and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Amifampridine, including Firdapse.
Yes. The US FDA first approved Amifampridine on 28 November 2018, according to Drugs@FDA.
Yes. Amifampridine has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Amifampridine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Amifampridine is classified under ATC code N07XX05 (Amifampridine).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.